Evidence map›Paper›PMID 41927700›Full record

Trial reportScientific reports2026

A randomized comparison of etoposide and cyclophosphamide for stem cell mobilization in newly diagnosed multiple myeloma.

Yao Sun, Jieping Li, Yujun Dong, Meng Li, Yueqi Wang, Xilin Chen, Shunzong Yuan, Yun Lu, Yi Ma, Junli Chen and 4 more

Abstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yao Sun *Senior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China.
Jieping Li *Department of Hematology and Lymphoma, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Yujun Dong *Department of Hematology, Peking University First Hospital, Beijing, China.
Meng Li *Senior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China.
Yueqi Wang *Senior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China.
Xilin ChenSenior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China.
Shunzong YuanSenior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China.
Yun LuSenior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China.
Yi MaSenior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China.
Junli ChenSenior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China.
Wen GaoDepartment of Hematology, Beijing Chaoyang Hospital, Myeloma Research Center of Beijing, Capital Medical University, Beijing, China. gaowenpingping@163.com.
Wenrong HuangSenior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China. huangwenrong@301hospital.com.cn.
Yao LiuDepartment of Hematology-Oncology, Affiliated Cancer Hospital of Chongqing University, Chongqing, China. liuyao77@cqu.edu.cn.
Xiubin XiaoSenior Department of Hematology, Chinese People's Liberation Army General Hospital, 8 East Street, Fengtai District, Beijing, 100071, China. xiaoxb2021@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Successful autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) patients relies on the efficient mobilization of hematopoietic stem cells following induction therapy. While the efficacy of etoposide for stem cell mobilization has been demonstrated in numerous studies, a randomized comparison of the efficacy of cyclophosphamide versus etoposide has previously been lacking. This randomized, open-label, multicenter trial enrolled NDMM patients eligible for ASCT. The inclusion criteria were patients with a diagnosis of NDMM who required stem cell mobilization prior to ASCT. Patients were randomly assigned to receive either high-dose etoposide (VP16; 1.2 g/m

Indexed as

CyclophosphamideEtoposideHematopoietic Stem Cell MobilizationMultiple MyelomaAdultAgedAntigens, CD34FemaleGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedTransplantation, AutologousTreatment OutcomeAntigens, CD34CyclophosphamideEtoposideGranulocyte Colony-Stimulating Factor​Autologous Stem Cell Transplantation​Cyclophosphamide​Etoposide​Mobilization​Multiple Myeloma

Identifiers

PMID41927700
PMCPMC13195070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.